Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Mouse models of human cancer are a potential preclinical setting for drug testing and for development of methods for delivery of macromolecular drugs to tumors. We have assessed a mouse model of leukemia caused by Mll-Enl protein fusion as a preclinical situation in which myeloid-lineage leukemia results from de novo occurrence of chromosomal translocations between Mll and Enl genes. Here, we show that the mouse leukemias respond to cytosine arabinoside, a frontline treatment for human leukemia. The observations show that the myeloid cells are susceptible to the drug and the mice undergo a remission that comprises a reduction of the myeloid population of cells and recovery of the lymphoid population. This translocator model should therefore prove useful for future drug assessments against the recurrent mixed-lineage leukemia-associated translocations.

Original publication

DOI

10.1158/1535-7163.MCT-07-2032

Type

Journal article

Journal

Mol Cancer Ther

Publication Date

03/2008

Volume

7

Pages

730 - 735

Keywords

Animals, Antineoplastic Agents, Cell Line, Tumor, Cytarabine, Leukemia, Experimental, Mice, Models, Theoretical, Myeloid-Lymphoid Leukemia Protein, Oncogene Proteins, Fusion